Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-09-30
|
brodalumab (AMG 827) |
psoriasis |
3 |
Amgen (USA - CA) AstraZeneca (UK) |
Autoimmune diseases - Dermatological diseases |
2015-09-30
|
TEV-48125 (formerly LBR-101/ RN-307) |
migraine |
2b |
Teva Pharmaceutical Industries (Israel) |
CNS diseases |
2015-09-30
|
brodalumab (AMG 827) |
psoriasis |
3 |
Amgen (USA - CA) AstraZeneca (UK) |
Autoimmune diseases - Dermatological diseases |
2015-09-29
|
CAD106 and CNP520 |
Alzheimer's disease |
2-3 |
Novartis Pharmaceuticals (Switzerland) Banner Alzheimer\'s Institute (USA - Denmark) National Institute on Aging (NIA) (USA) Alzheimer\'s Association (USA) |
Neurodegenerative diseases |
2015-09-29
|
PV-10 |
|
preclinical |
Provectus Pharmaceuticals (USA - TN) |
Cancer - Oncology |
2015-09-29
|
mesenchymal precursor cells (MPCs) |
end-stage or class IV New York Heart Association (NYHA) heart failure |
2 |
Mesoblast (Australia) |
Cardiovascular diseases |
2015-09-28
|
house dust mite SLIT-tablet/Miticure™ |
house dust mite allergy |
|
Torii Pharmaceutical (Japan) |
Allergic diseases - Immunological diseases - Respiratory diseases |
2015-09-28
|
ozanimod - RPC1063 |
multiple sclerosis |
3 |
Celgene (USA - NJ) |
Autoimmune diseases - Neurodegenerative diseases |
2015-09-28
|
custirsen |
metastatic castrate-resistant prostate cancer |
3 |
OncoGenex Pharmaceuticals (USA - WA) |
Cancer - Oncology |
2015-09-28
|
CHEMOSAT® Delivery System |
liver metastases from ocular melanoma |
|
Delcath Systems (USA - NY) |
Cancer - Oncology |
2015-09-28
|
IPH2201 (anti-NKG2A antibody) |
ovarian Cancer, Fallopian tube cancer, peritoneal cancer |
1-2 |
NCIC Clinical Trials Group (Canada) Innate Pharma (France) |
Cancer - Oncology |
2015-09-28
|
ALLOB® |
failed spinal fusion |
2a |
Bone Therapeutics (Belgium) |
Bone diseases - Regenerative medicine |
2015-09-27
|
lenvatinib |
thyroid cancer |
3 |
Eisai (Japan) |
Cancer - Oncology |
2015-09-27
|
atezolizumab (MPDL3280A) |
locally advanced or metastatic urothelial bladder cancer (UBC) that had progressed on initial treatment |
2 |
Roche (Switzerland) |
Cancer - Oncology |
2015-09-27
|
Opdivo® (nivolumab) |
non-squamous non-small cell lung cancer (NSCLC) |
3 |
BMS (USA - NY) |
Cancer - Oncology |
2015-09-26
|
Xtandi® (enzalutamide) |
advanced, androgen receptor (AR)-positive, triple-negative breast cancer (TNBC) |
2 |
Medivation (USA - CA) Astellas (Japan) |
Cancer - Oncology |
2015-09-25
|
GLPG0634 (filgotinib) |
rheumatoid arthritis |
2b |
Galapagos (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2015-09-25
|
pembrolizumab (MK-3475) |
oesophageal carcinoma, oesophagogastric junction carcinoma |
3 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2015-09-25
|
Opdivo® (nivolumab) |
advanced or metastatic (medically or surgically unresectable) clear-cell renal cell carcinoma |
3 |
BMS (USA - NY) Ono Pharmaceutical (Japan) |
Cancer - Oncology |
2015-09-24
|
talacotuzumab (JNJ-56022473) |
acute myeloid leukemia (AML) |
2 |
Janssen Biotech, a J&J company (USA - NJ) |
Cancer - Oncology |